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Abstract
Robust associations between lipoprotein(a) [Lp(a)] and CVD outcomes among general populations have been
published in previous studies. However, associations in high risk primary prevention and secondary prevention
populations are less well defined. In order to investigate this further, a systematic review was performed including
prospective studies, which assessed the relationship between Lp(a) and CVD outcomes using multivariable analyses.
Additional information was gathered on Lp(a) assays, multivariable modelling and population characteristics.
Literature searches from inception up to December 2015 retrieved 2850 records. From these 60 studies were
included. Across 39 primary prevention studies in the general population (hazard ratios ranged from 1.16 to 2.97)
and seven high risk primary prevention studies (hazard ratios ranged from 1.01 to 3.7), there was evidence of a
statistically significant relationship between increased Lp(a) and an increased risk of future CVD. Results in 14 studies
of secondary prevention populations were also suggestive of a modest statistically significant relationship (hazard
ratios ranged from 0.75 to 3.7).
Therefore current evidence would suggest that increased Lp(a) levels are associated with modest increases in the
risk of future CVD events in both general and higher risk populations. However, further studies are required to
confirm these findings.
Keywords: Atherosclerosis, Epidemiology, Lipids, Lipoprotein, Cardiovascular risk
Background
Cardiovascular disease (CVD) is a leading cause of death
and disability [1, 2]. Elevated levels of low-density
lipoprotein cholesterol (LDL-C) are a major contributor to
atherosclerosis leading to subsequent CVD events. Numer-
ous clinical trials of lipid lowering drugs have found that re-
ducing LDL-C levels substantially reduces the risk of CVD
[3–5] suggesting a strong direct relationship between
plasma LDL-C levels and CVD outcomes [6, 7]. Many
people, however, still have residual CVD risk and suffer
from CVD events despite significant LDL-C lowering. In
addition to LDL-C, other risk factors are likely to influence
residual cardiovascular risk. Among these, lipoprotein(a)
[Lp(a)], has been proposed to be independently associated
with CVD [8].
Lp(a) is an low density lipoprotein (LDL) particle
which is attached to the polypeptide, apolipoprotein(a)
[apo(a)] [9]. Apo(a) exists in multiple forms or ‘kringles’,
which give rise to different Lp(a) isoforms. Apo(a) is also
believed to be responsible for the anti-fibrinolytic prop-
erties of Lp(a) [9]. Further biomechanisms behind the
Lp(a) and CVD relationship may also involve prothrom-
botic or proatherosclerotic processes, or a combination
of the two [10].
Lp(a) may be measured using a variety of different
assays. However, the reliability of many of the assays is
questionable, due to their poor abilities at detecting the
multiple molecular isoforms of Lp(a). Consequently,
some assays (isoform dependent) that measure Lp(a)
mass cannot distinguish between high and low molecular
weight apo(a) isoforms, whilst others (isoform independ-
ent) can. However, to our knowledge, at present there
appear to be no Lp(a) assays that are both isoform inde-
pendent and suited for use clinical laboratories [11]. This
problem has led to poor standardisation and comparability
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with respect to the Lp(a) values recorded by different
assays, which in turn hampers comparisons between trials
assessing the relationship between Lp(a) and CVD [12].
Despite this clinical trials have shown that Lp(a) is a risk
factor in patients on long-term statin treatment [13, 14].
Evidence from the Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglycerides:
Impact on Global Health Outcomes (AIM-HIGH) trial
suggests that Lp(a) is a predictor of CVD events in pa-
tients with normal LDL-C levels [15] and recent studies
have suggested that elevated Lp(a) levels like elevated
LDL-C, could be associated with premature CVD [8].
Extensive research exists to support an association be-
tween Lp(a) and CVD events with respect to the primary
prevention of events in the general population [16, 17].
This relationship appears to be independent of LDL-C,
other lipid levels such as high density lipoprotein (HDL)
and the presence of other cardiovascular risk factors [18].
Some evidence from pooled analyses of prospective stud-
ies [19–21] suggests a potential association between Lp(a)
and risk of CVD among high risk and secondary preven-
tion population. The availability of new data from recently
published clinical studies has prompted the need for a
more contemporary systematic review. This review
assesses the relationship between Lp(a) and CVD out-
comes, with particular emphasis on high cardiovascular
risk populations (high risk primary prevention and sec-
ondary prevention). The review also focuses on the best
available evidence from studies that used multivariable
analysis methods to control for the effect of confounding
variables.
Methods
To reduce the risks of bias and error, this review
adhered to a pre-specified protocol and methods recom-
mended by the Cochrane Collaboration [22], and the
Centre for Reviews and Dissemination (York, United
Kingdom) [23] which are widely regarded as ‘gold standard’
methodologies.
This review included prospective studies, which
assessed the relationship between Lp(a) and CVD out-
comes. These studies included randomised controlled
trials (RCTs), cohort studies and nested case-control
studies. Eligible populations were any adult (≥18 years)
population regardless of baseline CVD risk, gender, age
and ethnicity. Studies had to follow patients for at least
12 months. No restrictions were placed on the CVD
outcome or the type of Lp(a) assay. However, studies
were required to use a multivariable analytical approach,
which assessed the effect of Lp(a) on CVD outcomes
after adjusting for other confounding factors. At a
minimum the analysis had to adjust for baseline age and
gender; but this restriction was relaxed for studies in
gender and age subgroups or in nested case-control
studies where cases and controls were matched on age
and gender. Studies were excluded from the review if
they fail to clearly report effect sizes based on relevant
multivariable analyses.
Extensive literature searches were performed using
search strategies developed by an Information Specialist
(full strategies are available in Additional file 1). A total
of six electronic databases were searched from inception
to 31 December 2015 including: MEDLINE, Embase,
Medline In-Process & Daily Update, Cochrane Central
Register of Controlled Trials (CENTRAL), Database of
Abstracts of Reviews of Effects (DARE) and the
Cochrane Database of Systematic Reviews (CDSR).
Search strategies were refined and adapted according to
the configuration and requirements of each database.
The final strategies combined relevant search terms
comprising indexed keywords (e.g. Medical Subject
Headings, MeSH and EMTREE) and free text terms
appearing in the title and/or abstract of database re-
cords. Search terms were identified through discussion
between the review team, by scanning background litera-
ture and ‘key articles’ already known to the review team,
and by browsing database thesauri. Literature searches
were not limited by date, language or publication status.
Supplementary searches were undertaken in two trials reg-
isters (National Institutes of Health [NIH] ClinicalTrials.-
gov and International Standard Randomised Controlled
Trial Number [ISRCTN] Registry) and conference ab-
stracts from four major cardiovascular disease conferences
(European Atherosclerosis Society Congress; European So-
ciety of Cardiology Congress; American College of Cardi-
ology Annual Scientific Session; and American Heart
Association Annual Scientific Sessions, for years 2011-
2015). The reference lists of included studies and system-
atic reviews were checked for further studies. Identified ref-
erences were downloaded in Endnote X6 software
(Thomson Reuters, New York) for further assessment and
handling, and duplicate records were removed.
The study selection process was performed by two re-
viewers working independently. Data were extracted into
a specifically developed spreadsheet in Excel 2010 (Micro-
soft Corporation, Redmond, Washington). One reviewer
extracted the study data and a second reviewer independ-
ently reviewed the data against the original paper for com-
pleteness and accuracy. Data were extracted on the
baseline population (e.g. race and previous CVD events),
Lp(a) assay (e.g. isoform independence), CVD outcomes,
statistical analysis methods (details of the type of multivar-
iable model and the variables included) and effect sizes for
the relationship between Lp(a) and CVD outcomes.
The methodological quality (risk of bias) of each
study was assessed using the criteria of the Quality in
Prognostic Studies (QUIPS) tool [24]. The quality assess-
ments were performed independently by two reviewers.
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Any discrepancies between reviewers during data extrac-
tion or quality assessments were resolved through consen-
sus or consultation with a third reviewer.
Meta-analysis was not possible due to heterogeneity in
the CVD outcomes, populations and statistical analysis
methods. Studies have been summarized in a narrative
synthesis accompanied by data tables. It was not possible
to plot data on Forest plots due to the absence of neces-
sary data. Effect sizes for Lp(a) are reported as odds ra-
tios (ORs), hazard ratios (HRs) or adjusted Lp(a) levels
with accompanying 95 % confidence intervals (CIs) or
means/interquartile ranges (IQR). Studies are grouped
according to CVD outcome, population and variables in-
cluded in the multivariable model(s). The term “positive”
association refers to an increase in Lp(a) or higher Lp(a)
levels resulting in an increased risk of CVD outcomes.
Similarly a “negative” association refers to an increase in
Lp(a) or higher Lp(a) levels resulting in a decreased risk
of CVD outcomes.
Results
Literature searches of electronic databases and other
sources including hand searching retrieved 3837 titles/
abstracts through December 2015. After de-duplication,
a total of 2850 titles/abstracts were screened, and 2189
papers were excluded as having no relevance to the re-
view. Full papers of 312 potentially relevant references
were selected for further examination. Of these, 197 pa-
pers were excluded after further examination for the fol-
lowing reasons: do not report relevant prognostic factors
(20 papers), not relevant outcome (32 papers), not rele-
vant study design (103 papers), and no clearly reported
multivariable analysis (42 papers). A total of 60 studies
(115 papers) met the criteria for inclusion in the review.
A summary of the identification and selection of stud-
ies for inclusion in this review is presented in Fig. 1, in
accordance with the PRISMA [25].
The 60 studies included ten RCTs, 37 prospective co-
hort studies and 13 nested case control studies. A sum-
mary of the studies is reported in Table 1 and further
information about individual studies is available in an
Additional file 2: Table S1.
Overall, across all 60 studies, the level of bias was
assessed as moderate. However 13 studies were assessed
as having a high risk of bias and five studies as a low risk
of bias; 11 studies failed to report sufficient detail so as
to allow a full assessment of the risk of bias. Those studies
that were of high risk of bias often had methodological is-
sues within the QUIPS domains 2 and 3 concerning study
attrition and prognostic factor [i.e. Lp(a)] measurement
respectively. Reporting across studies was not always suffi-
ciently detailed to allow a judgement to be made and 16
studies were reported as not having enough information
to make a judgement for at least one of the six QUIPS
criteria. Further details of the risk of bias assessments for
the individual studies are available in a Additional file 3:
Table S2.
Primary prevention studies
The majority of the identified studies (39 studies) were
carried out in participants from the general population,
i.e. did not select patients based on their baseline history
or risk of CVD events. Further details of the characteris-
tics of the studies in the general population are reported
in Table 2. These included four RCTs, 25 prospective co-
hort studies and 10 nested case-control studies. Thirteen
studies [26–38] were conducted in males and two in fe-
males [39, 40]. Specific ethnic groups were used in some
studies including populations from South Korea [41, 42],
Native American Indians (from the USA) [43], Japan
[44, 45] and Taiwan [46]. Follow-up in the studies
tended to be longer than in the high risk and secondary
prevention populations, with 20 out of 39 studies (52.3 %)
having a follow-up of 5 to ≤ 10 years and 11 out of 39
studies; 28.2 %) following participants for over 10 yrs. The
longest follow-up period was 20 years in the ARIC study
[47]. The risk of bias across the 39 studies was assessed as
low in two studies (5.4 %); moderate in 22 studies
(84.0 %), high in seven studies (17.9 %) and there was in-
sufficient information to make an assessment in eight
(20.5 %) studies. Only 12 (30.8 %) studies used assays that
were reported as isoform independent and five (12.8 %)
used assays on fresh plasma samples. The majority of
studies used a Cox proportional hazards model (20 stud-
ies; 51.3 %); other models included logistic regression (11
studies; 28.2 %), conditional logistic regression (seven
studies; 17.9 %), and both conditional and unconditional
logistic regression (one study; 2.6 %).
Half of the studies included LDL-C (19 studies;
48.7 %) as a covariate in the multivariable model and all
but four of these studies (Justification for the Use of
Statins in Primary Prevention: An Intervention Trial
Evaluating Rosuvastatin trial [JUPITER] [14], PRospect-
ive du l’Infarctus MyocardE; prospective epidemiological
study of myocardial infarction [PRIME] [34], Invecchiare
in Chianti [InCHIANTI] Study [48] and Atherosclerosis
Risk in Communities [ARIC] [49]) reported significant
positive associations between Lp(a) and CVD. The JUPI-
TER study [14] and PRIME [34] each reported two nega-
tive associations between Lp(a) and CVD events, but in
both cases these were for subgroup analyses and the
results were not statistically significant. In the case of
the JUPITER study [14] the authors concluded that
among white participants treated with potent statin ther-
apy, Lp(a) concentrations (at baseline and on-statin)
were a significant determinant of residual risk with re-
spect to CVD events; and in the PRIME study [34] that
increased baseline Lp(a) levels (considered as the Lp(a)
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cholesterol content) were significantly associated with
the risk for MI and angina pectoris, especially in men
with high LDL-C. In the ARIC study [49] a significant
negative association with Lp(a) mass was reported for a
subgroup analysis of ischemic strokes in white females,
when comparing >6.6 to ≤ 14.6 mg/dL Lp(a) [Quintile 4]
versus 0.1 to ≤ 1.6/dL Lp(a) [Quintile 1]. However, this
result was based on a small number of events suggesting
that it may not be robust and was in contrast to the
overall trend of the other primary and subgroup ana-
lyses, which suggested that overall a positive association
existed between Lp(a) mass and CVD events. Overall,
the authors concluded that Lp(a) mass was positively as-
sociated with CVD events, but that it appeared stronger
in blacks compared to whites. The InCHIANTI study
[48] did not report any statistically significant associa-
tions after following patients longitudinally for six years,
but did find evidence of a link between prevalent periph-
eral arterial disease (PAD) and Lp(a). The authors con-
cluded that Lp(a) concentration was an independent
predictor of PAD in the cross-sectional evaluation, but
that further larger, longer duration, prospective studies
are needed to establish a longitudinal association.
Among the remaining half of the studies which did
not include LDL-C as a covariate in their multivariable
models, a further four studies (Physician’s Health Study
[PHS] [33, 50], Italian Longitudinal Study on Aging
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Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the selection of studies
Forbes et al. Lipids in Health and Disease  (2016) 15:95 Page 4 of 20




















































































































13 30 5 11 35 15 1 0 2 7 21
no. number; std. studies















[USLM] [26] and Women’s Health Initiative Observa-
tional Study/Hormones and Biomarkers Predicting
Stroke Studies[WHI-OS/HaBPS] [39]) reported some
negative associations between Lp(a) mass and CVD
events. Negative statistically insignificant associations in
the USLM study [26] were reported for the relationship
between Lp(a) mass and intracerebral haemorrhage, but
the authors concluded that high serum Lp(a) level inde-
pendently predicted fatal and non-fatal stroke/transient is-
chemic attack (TIA) in a population of middle-aged men
followed for 32 years. In the ILSA study [51] no overall
statistically significant association was found between high
Lp(a) levels and the risk of all-cause mortality, cumulative
fatal–nonfatal stroke, and cumulative fatal–nonfatal cor-
onary artery disease (CAD) events. However, the authors
reported that high Lp(a) levels were an independent and
significant predictor of non-fatal CAD events after
6.3 years in an elderly (65 to 84 years) population [51]. No
association was also reported for Lp(a) concentration and
ischemic stroke in the WHI-OS/HaBPS [39] study, where
the authors concluded that they found no significant rela-
tionship between Lp(a) and ischemic stroke in postmeno-
pausal women. However, the methods used to measure
Lp(a) were not well described in this study and so their re-
liability was unclear. The PHS study [33] also found no
evidence that Lp(a) levels were a significant predictor of
PAD in men.
High risk primary prevention studies
Seven studies assessed the relationship between Lp(a)
and CVD outcomes in populations at high risk of CVD
events, but who had not as yet experienced a CVD event
(Agewall 2002; [52] Choices for Healthy Outcomes in
Caring for End Stage Renal Disease study [CHOICE];
[53] Cleveland Clinic Hemodialysis Cohort; [54] Dia-
mant Alpin Collaborative Dialysis Cohort; [55] Japan
Diabetes Complications Study [JDCS]; [56] Koda 1999;
[57] and Zimmermann 1999 [58]). Follow-up in the
studies ranged from 2 years [14, 55, 57] to 7.8 years [56]
and the sample size ranged from 118 [59] to 1494 [60]
participants. These studies included patients with hyper-
tension [52, 55], dialysis patients [55, 57, 58, 61, 62] and
patients with diabetes [55–57, 63]. Five studies were in
mixed gender populations [54–58, 61, 64], with one
study in older (aged 56 to 77 yrs) males [52]. Two of the
studies were in Japanese populations [56, 57]. A sum-
mary of the characteristics and effect sizes for these
studies is shown in Table 3.
The overall quality of the six prospective cohort studies
[53–55, 57, 58, 64] and one RCT [65] was mixed, with the
risk of bias assessed as high in four studies [52, 55–57],
moderate in two studies [54, 61] and low in one study [58].
CVD outcomes assessed in the studies were individual
and composite outcomes including coronary heart disease
Table 2 Summary of primary prevention studies in the general
population (39 studies)
Item Category Number of
studies (%)
Study design RCT 4/39 (10.3 %)
Prospective cohort study 25/39 (64.1 %)
Nested case-control study 10/39 (25.6 %)
Follow-up 1 yr to <2 yrs 1/39 (2.6 %)
2 yrs to <5 yrs 4/39 (10.3 %)
5 yrs to <10 yrs 20/39 (52.3 %)
10 yrs+ 11/39 (28.2 %)
Not reported or unclear 3/39 (7.7 %)
Gender Males only 13/39 (33.3 %)
Females only 2/39 (5.1 %)
Mixed males and females 24/39 (61.5 %)
Age <65 yrs 36/39 (92.3 %)
Elderly ≥ 65 yrs 3/39 (7.7 %)
Ethnicity Mixed 3/39 (7.7 %)
Korean 2/39 (5.1 %)
Taiwanese 1/39 (2.6 %)
Japanese 1/39 (2.6 %)
Native American Indian 1/39 (2.6 %)
White (majority populations) 15/39 (38.5 %)
Not reported/unclear 16/39 (41.0 %)
Model methoda Cox proportional hazards 20/39 (51.3 %)




Conditional logistic regression 7/39 (17.9 %)
Discriminant analysis 0/39 (0 %)
Model variables Includes LDL-C as model variable 19/39 (48.7 %)
Does not include LDL-C or unclear/
not reported
19/39 (48.7 %)
Lp(a) assay Isoform dependent 1/39 (2.6 %)




Isoform independence NR or unclear 25/39 (61.4 %)
Sample type Fresh plasma samples 5/39 (12.8 %)
Frozen plasma samples 25/39 (64.1 %)
Mixture of frozen and fresh samples 2/39 (5.1 %)
Not reported or unclear 7/39 (17.9 %)
Risk of bias Low 2/39 (5.1 %)
Moderate 22/39 (56.4 %)
High 7/39 (17.9 %)
Not enough information 8/39 (20.5 %)
LDL-C low density lipoprotein; Lp(a) lipoprotein (a); NR not reported; RCT
randomised controlled trial; yrs years
aNote some studies report multiple types of models
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Table 3 Summary of primary prevention studies in high risk populations (7 studies)
Study Details Analysis Methods Summary of findings
Agewall 2002 [52] (n = 118)
Study design: Prospective cohort study
Follow-up: 3.0 ± 0.6 yrs
Population description: Males 56 to 77 yrs with
treated hypertension
Overall risk of biasa: High risk
Funding: NR
Model: Cox proportional hazards
Variables: Age and other variables; LDL-C not included
CVD Outcomes: Non-fatal MI or CD
Lp(a) assay: Isoform independence - NR; NR if fresh or
frozen samples
Lp(a) comparison type: Continuous
Two effects sizes reported, each using a different model for the
relationship between log per Lp(a) increase and non-fatal MI or CD:
HR 2.84, 95 % CI: 1.06 to 7.63 (adjusted for age, BP, smoking,
cholesterol, diabetes)
HR 2.97, 95 % CI: 1.03 to 8.37 (adjusted for CD at entry)
Both were statistically significant showing that Lp(a) is a significant and
independent predictor for major coronary events
CHOICE [53] (n = 833)
Study design: Prospective cohort study
Follow-up: Median 27.4 mths
Population description: Mixed gender adults
17 yrs + on dialysis
Overall risk of biasa: Moderate risk
Funding: Public/government
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C
not included
CVD Outcomes: ASCVD
Lp(a) assay: Isoform independent;
frozen samples
Lp(a) comparison type: Categorical
Ten effect sizes reported from five models of two categorical comparisons.
Nine out of ten showed a statistically significant, positive association
(same direction) for Lp(a) with respect to ASCVD.
Maximum effect size reported was for Lp(a) ≥ 206 nmol/L (ref) vs.
Lp(a) < 206 nmol/L (HR 1.89, 95 % CI: 1.3 to 2.75).
One effect size was NS: Lp(a)≥ 52.5 nmol/L (ref) vs. Lp(a) <52.5 nmol/L
(HR 1.25, 95 % CI: 0.99 to 1.58)
The authors concluded that ASCVD was significantly and independently
associated with high Lp(a) (>123 nmol/L) and low molecular weight (LMW)
apo(a) isoforms, though a stronger relationship was found for ASCVD and
low molecular weight isoform size. This is in ESRD patients and there was
a high transplantation rate (17.3 %) which may have biased the Lp(a) results
Cleveland Clinic Hemodialysis Cohort [54] (n = 129)
Study design: Prospective cohort study
Follow-up: 4 yrs
Population description: Mixed gender adults ≥ 18 yrs
on haemodialysis
Risk of bias assessment overalla: Moderate risk
Funding: Public/government
Model: Multiple regression (OR) and Cox proportional
hazards (HR)
Variables: Gender and other variables; includes LDL-C
CVD Outcomes: Atherosclerotic events including stroke
and MI
Lp(a) assay: Isoform independence -NR/unclear; frozen
samples
Lp(a) comparison type: Continuous
Two effect sizes reported for Lp(a) with respect to atherosclerotic events:
OR 1.02, 95 % CI: 1.01 to 1.04 (multiple regression)
HR 1.603, 95 % CI: 1.08 to 2.38 (Cox proportional)
A 1-mg/dL or 10-mg/dlL increment in baseline Lp(a) concentration was
associated with a 1.02 or 1.26 increase, respectively, in the relative risk of
sustaining an event (p = 0.001)
Both results suggested that baseline Lp(a) is a significant and independent
risk factor for clinical events
Diamant Alpin Collaborative Dialysis Cohort [55] (n = 279)
Study design: Prospective cohort study
Follow-up:2 yrs
Population description:
Mixed gender adults 22 to 92 yrs with and without
type 2 diabetes
Risk of bias assessment overalla: High risk
Funding: Pharma
Model: Cox proportional hazards regression
Variables: Age, gender and other variables; LDL-C
not included
CVD Outcomes: CVD events (MI, de novo angina
pectoris or coronary
revascularization, ischemic stroke, or PAD) and CV
death (due to cardiac
arrhythmia, MI, or HF)
Lp(a) assay: NR/unclear; Immunoturbidimetric assay;
Isoform dependence -
NR/unclear; NR if fresh or frozen samples
Lp(a) comparison type: Categorical
One effect size reported which showed a statistically significant positive
association (same direction) for Lp(a) > 300 mg/L vs≤ 300 with CVD events
and CV deaths: HR 1.67, 95 % CI: 1.04 to 2.63
This result suggested that Lp(a) is an independent and significant predictor
of CV events.
JDCS [56] (n = 1304)
Study design: RCT
Follow-up: Median 7.8 yrs
Population description: Mixed gender Japanese adults
40 to 70 yrs with Type 2 diabetes
Risk of bias assessment overalla: High risk
Funding: Public/government
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C
not included
CVD Outcomes: Stroke (ischemic, hemorrhagic
or TIA), CHD
Lp(a) assay: Isoform independence -NR/unclear;
frozen samples
Lp(a) comparison type: Continuous
One effect size reported which showed a statistically significant positive
association (same direction) of Lp(a) (per 1 μmol/l increase) with an
increased risk of stroke (ischemic, hemorrhagic or TIA): HR 1.16, 95 %
CI: 1.03 to 1.31
















Table 3 Summary of primary prevention studies in high risk populations (7 studies) (Continued)
Koda 1999 [57] (n = 390)
Study design: Prospective cohort study
Follow-up:2.3 yrs
Population description:
Mixed gender Japanese adults≥ 18 yrs with or
without type 2 diabetes receiving haemodialysis
Risk of bias assessment overalla: High risk
Funding: NR/unclear
Model: Multiple logistic regression model
Variables: Age, gender, albumin, Lp(a), diabetic state;
LDL-C not included
CVD Outcomes: Death and CV death
Lp(a) assay: NR/unclear; Immunoturbidimetric assay;
Isoform dependence -
NR/unclear; NR if fresh or frozen samples
Lp(a) comparison type: Categorical
One effect size reported for Lp(a) showed a statistically significant positive
association (same direction) with respect to CV death, comparing High
Lp(a) [≥ 30 mg/dL] vs Low Lp(a) [< 30 mg/dL]: OR 3.93, 95 % CI: NR. This
association was statistically significant.
One effect size reported for Lp(a) with respect to overall death, comparing
High Lp(a) [≥ 30 mg/dL] vs Low Lp(a) [< 30 mg/dL]: OR 1.97 95 % CI: NR.
This association was not statistically significant.
Suggests that high Lp(a) [≥ 30 mg/dL] is an independent and significant
risk factor for atherosclerotic CV death, but not overall death.
Zimmermann 1999 [58] (n = 440)
Study design: Prospective cohort study
Follow-up: 12 and 24mths
Population description: White mixed gender adults
20 to 88 yrs on chronic haemodialysis
Risk of bias assessment overalla: Low risk
Funding: Public/government
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: All deaths, stroke, HF, MI
Lp(a) assay: Isoform independence - NR; fresh samples
Lp(a) comparison type: Categorical
Lp(a) was significantly associated with risk of all-cause and cardiovascular
mortality in univariate Cox regression analysis, but was not significant in
the multivariable Cox regression analysis.
This study is in haemodialysis patients, in such patients Lp(a) reacts as an
acute phase protein in combination with other factors such as fibrinogen,
HDL-C and Apo A-I, changing the atherogenic risk profile. When Lp(a) is
added to the multivariable model with these other variables Lp(a) no
longer remains significant as an independent factor.
aRisk of bias according to Quality In Prognosis Studies (QUIPS) risk of bias assessment tool [24]
ASCVD atherosclerotic cardiovascular disease; CD coronary death; CHD coronary heart disease; CHOICE Choices for Healthy Outcomes in Caring for ESRD; CI confidence interval; CVD cardiovascular events; ESRD end
stage renal disease; HF heart failure; HR hazard ratio; JDCS Japan Diabetes Complications Study; LDL-C low density lipoprotein cholesterol; OR odds ratio; MI myocardial infarction; mth months; NR not reported; NS not















(CHD) [56], non-fatal myocardial infarction (MI) [52, 55],
cardiovascular death [52, 55, 57], atherosclerotic events
[53, 54], non-haemorrhagic stroke [54, 65], heart failure
(HF) [58], TIA [56] and all deaths [57, 58]. Six studies
used Cox proportional hazards models [54–56, 58, 61, 64],
with one study reporting results from stepwise multiple
logistic and Cox regression analyses [54]. and one report-
ing a multiple logistic regression model [57]. Age was
considered as a variable in all but one study [54], and simi-
larly gender was considered in all but one study [52]. All
of the studies included additional variables. These varied
in type and number across the studies and studies re-
ported different results for models adjusted with different
groups of variables. However, only one study included
LDL-C in their model [54]. This study (Cleveland Clinic
Hemodialysis Cohort) [54] found that baseline Lp(a)
concentration was a significant independent risk fac-
tor (p = 0.001) for clinical events attributed to athero-
sclerotic cardiovascular disease in patients receiving
chronic haemodialysis treatment of end-stage renal
disease. The only study to report the use of an iso-
form independent Lp(a) assay (CHOICE [53]) simi-
larly reported that high Lp(a) levels (≥52.5 nmol/L)
predicted a 30 % to 40 % increased risk of elevated
atherosclerotic cardiovascular disease (ASCVD) in dia-
lysis patients, but that the association of ASCVD with
low molecular weight LMW isoforms (increased risk
of 60 % to 90 %) was stronger than the association
with high Lp(a) concentration.
In half of the studies Lp(a) levels were included as a
continuous variable and the other half of the studies
used categorical data. Of the eight studies, only one
failed to find a significant relationship between Lp(a)
and CVD outcomes (Zimmermann 1999 [58]). This
study in haemodialysis patients reported that serum
Lp(a) concentration was a significant predictor in uni-
variate analyses, but that significance was lost when
Lp(a) concentration was included in multivariable
models for death and cardiovascular death [58]. This
study was carried out in stable haemodialysis patients
measuring outcomes at two years and the authors sug-
gested that Lp(a) was only involved in an acute phase re-
action. All of the remaining studies showed a positive
association, i.e. that increased Lp(a) levels increased the
risk of CVD events; hazard ratios (HRs) ranged from
1.16 to 2.97.
Secondary prevention studies
Fourteen studies assessed the relationship between Lp(a)
and CVD outcomes in patients with previous CVD events
(Scandinavian Simvastatin Survival Study [4S Study]; [66]
Atherothrombosis Intervention in Metabolic Syndrome
With Low HDL/High Triglycerides: Impact on Global
Health Outcome trial [AIM–HIGH]; [67] Ezhov 2014;
[68] Global Evaluation of New Events and Restenosis After
Stent Implantation [GENERATION] study; [69] Heart
and Estrogen/progestin Replacement Study [HERS]; [70]
Ikenaga 2011; [71] Park 2015; [72] Konishi 2013; [45]
Kwon 2015; [73] Long-Term Intervention with Pravastatin
in Ischaemic Disease [LIPID] study; [13] Rapamycin-
Eluting Stent Evaluated At Rotterdam Cardiology Hospital
study [RESEARCH]; [74] Rosengren 1990; [75] Treating
to New Targets [TNT] study; [76] and Wehinger 1999
[77]). Follow-up in the studies ranged from 1 year [77] to
8.5 ± 3.5 years [68] and the sample size ranged from 115
[75] to 4444 [66] participants. These studies included pa-
tients with previous MI/CHD disease [63], [66, 70, 75, 76]
CAD; [73] stent placement after symptomatic CAD
[63, 72, 77], patients undergoing percutaneous coron-
ary intervention (PCI) [45, 71, 78], history of CVD
[13, 60, 67], patients after successful coronary artery
bypass graft (CABG) [68] and patients hospitalised for
stable angina, non-ST elevation acute coronary syndromes
(NSTACS) or ST-segment elevation myocardial infarction
(STEMI) [63, 69]. The majority of studies were in mixed
gender populations with the exception of two studies in
men [69, 75] and one in elderly postmenopausal women
[70]. Two of the studies were in Japanese populations
[45, 71] and two in Korean populations [72, 73]. A
summary of the characteristics and effect sizes for
these studies is shown in Table 4.
The overall quality of the eight prospective cohort
studies [45, 68, 69, 71–74, 77], one nested case-control
study [75] and five RCTs [13, 66, 67, 70, 76] was mixed,
with the risk of bias assessed as moderate in seven stud-
ies [13, 66, 72–75, 77] low in two studies [67, 68] and
high in two studies [45, 76]. There was insufficient infor-
mation to make a proper assessment in the remaining
three studies due to poor reporting [69–71].
CVD outcomes assessed in the studies were individual
and combined outcomes including the following: CHD
[70], non-fatal MI [13, 68–70, 75], cardiovascular death
[13, 75, 76], [69, 70, 79] stroke [67], MACE [66, 71–74],
hospitalisation for angina [68, 69], MI [70, 72, 76] TIA [67]
angiographic restenosis [72, 77] and all deaths [45, 66].
Twelve studies used Cox proportional hazards models [13,
67–74, 76, 77, 80], and two studies used logistic regression
[66, 75]. All of the studies considered age and gender in
their analyses. The other variables used in the analyses dif-
fered in type and number across the studies and on occa-
sions the studies reported results for models adjusted for
different groups of variables. Only two studies included
LDL-C level in their model (HERS [70] and Park
2015 [70, 72]) and binary restenosis and 3 yr adverse
clinical outcomes in an Asian population (Lp(a) >
50 mg/dL (versus Lp(a) ≤ 50 mg/dL [reference]: OR
2.88, 95 % CI: 1.37 to 6.07) [72]. In addition, one fur-
ther study (Kwon 2015 [73]) included the presence of
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Table 4 Summary of studies in secondary prevention (14 studies)
Study Details Analysis Methods Summary of findings
4S Study [66] (n = 4444)
Study design: RCT
Follow-up (median): 5.4 yrs (range 4.9-6.3)
Population description: Mixed gender aduts ≥
18 yrs with history of CHD
Risk of bias assessment overalla: Moderate
Funding: Mixed (foundation/public)
Model: Logistic regresssion
Variables: Age, gender and other variables; LDL-C
not included
CVD Outcomes: Death of any cause and MACE
Lp(a) assay: Isoform independence – NR/unclear;
frozen samples
Lp(a) comparison type: Categorical
Comparisons included were: Lp(a)≤ 38.25 units/l (ref) vs. 38.26-91 units/l,
91.1-289.75 units/l, ≥ 289.76 units/l
No effect sizes reported, but all six logistic regression analyses reported
a positive association, though this was only reported as statistically
significant for three out of six comparisons (two simvastatin arm
analyses and one placebo treatment arm).
The authors concluded that Lp(a) independently predicts major coronary
events as well as death in the secondary population.
AIM–HIGH [67] (n = 3414)
Study design: RCT
Follow-up: 3 yrs (at trial termination)
Population description: Mixed gender adults≥
45 yrs with established CVD and dyslipidemia
Risk of bias assessment overalla: Low
Funding: Mixed (induxstry/public)
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C
not included
CVD Outcomes: Ischemic stroke or TIA
Lp(a) assay: Isoform independence - NR; NR if fresh
or frozen samples
Lp(a) comparison type: Categorical
Four effect sizes reported, including two for ischemic stroke and two
for ischemic stroke or TIA. Comparisons were between lowest tertile
(reference) Lp(a) and moderate tertile or highest tertile (Lp(a) levels
not defined). All showed a statistically significant positive association
(same direction). The maximum effect size reported was HR 2.8,
95 % CI: 1.25 to 6.26 (lowest tertile vs. highest tertile) and the lowest
HR 2.3, 95 % CI: 1.19 to 4.42 (lowest tertile vs. highest tertile)
Results show an independent and significant association between
ischemic stroke and elevated baseline Lp(a) [middle/highest tertile]
Ezhov 2014 [68] (n = 356)
Study design: Prospective cohort study
Follow-up: 8.5 ± 3.5 yrs (range 0.9 -15.0 yrs)
Population description: Mixed gender adults≥
18 yrs with stable CHD after sucessful CABG
Risk of bias assessment overalla: Low
Funding: NR
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C
not included
CVD Outcomes: First cardiovascular event (non-fatal MI,
cardiovascular death, coronary revascularization, or
hospitalization for recurrent angina)
Lp(a) assay: Isoform independent; fresh samples
Lp(a) comparison type: Categorical
Two effect sizes reported, both were statistically significant showing a
positive association (same direction) between Lp(a) and non-fatal MI
or CD (< 30 mg/dl (reference) vs. ≥ 30 mg/dl: HR 2.98, 95 % CI: 1.76
to 5.03) and first ever major CVD event (< 30 mg/dl (ref) vs. ≥ 30 mg/dl:
HR 3.47, 95 % CI: 2.48 to 4.85)
These results show that Lp(a) concentration is independently
associated with three-fold increase in risk of major adverse
cardiovascular events within 15 years after CABG.
GENERATION [69] (n = 483)
Study design: Prospective cohort study
Follow-up: 1.84 yrs
Population description: Males adults≥ 18 yrs
admitted to hospital with the diagnosis of
either stable angina, NSTACS or STEMI
Risk of bias assessment overalla: Not enough
information
Funding: NR
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: Cardiac death; non-fatal MI; rehospitalisation
for rest-unstable angina
Lp(a) assay: Isoform independence – NR/unclear;
frozen samples
Lp(a) comparison type: Categorical
Four effect sizes reported for comparison of < 25 mg/dl (reference)
vs. ≥ 25 mg/dl.
Three were statistically significant showing a positive association
(same direction): HR 3.31, 95 % CI: 1.33 to 8.22 (non-fatal MI); HR
2.09, 95 % CI: 1.16 to 4.12 (rehosptialisation for angina); HR 2.42,
95 % CI: 1.52 to 3.84 (CD, non-fatal MI, hospitalisation for
unstable angina)
One was NS: HR 1.27, 95 % CI: 0.48 to 3.34 (death)
Authors concluded that high plasma levels of either CRP or Lp(a)
may be associated with the incidence of late events after successful
coronary stenting, but a more protracted latent period may be
needed in order to manifest clinically the unfavorable influence
of an elevated Lp(a) on atherosclerotic plaque instability. The authors
















Table 4 Summary of studies in secondary prevention (14 studies) (Continued)
HERS [70] (n = 2759)
Study design: RCT
Follow-up: 4.1 yrs
Population description: White elderly ≥ 50 yrs
postmenopausal females with CHD – placebo
group from RCT
Risk of bias assessment overalla: Not enough
information
Funding: Industry
Model: Cox proportional hazards
Variables: Age, gender and other variables; includes LDL-C
CVD Outcomes: Unstable angina; primary CHD events including
non-fatal MI and CHD death; MI
Lp(a) assay: Isoform independent; NR if fresh or frozen samples
Lp(a) comparison type: Categorical
15 effect sizes reported for 5 different sets of CVD events. Only 2/15
analyses were statistically significant showing a positive association
(same direction):
1st quartile (Lp(a) 0.0-7.0 mg/dl - reference) vs. 4th quartile (Lp(a) 55.0-236
mg/dl):HR 1.54, 95 % CI: 1 to 2.4 (primary CHD events, e.g non-fatal MI)
1st quartile (Lp(a) 0.0-7.0 mg/dl - reference) vs. 4th quartile (Lp(a) 55.0-236
mg/dl):HR 1.61, 95 % CI: 1.1 to 2.3 (CABG/PTCA)
Overall, the authors concluded that Lp(a) is an independent risk factor for
recurrent CHD in postmenopausal women.
Ikenaga 2011 [71] (n = 410)
Study design: Prospective cohort study
Follow-up: 5 yrs
Population description: Japanese mixed gender
adults≥ 18 yrs with PCI after MI: Lp(a) ≥ 40 mg/dl
Risk of bias assessment overalla: Not enough
information
Funding: No financial support
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: MACE (cardiac death, MI and/or revascularisation
for new lesions); revascularisation for new lesions
Lp(a) assay: Isoform independence – NR/unclear; NR if fresh
or frozen samples
Lp(a) comparison type: Categorical
Two effect sizes reported and both statistically significant showing a positive
association: ≤ 40 mg/dl (reference) vs. > 40 mg/dl: HR 1.64, 95 % CI: 1.31 to
2.06 (MACE)
≤ 40 mg/dl (reference) vs. > 40 mg/dl: HR 1.61, 95 % CI: 1.32 to 2.13
(revascularisation for new lesions)
Results show that Lp(a) levels can significantly and independently predict the
progression of non-culprit lesions after acute MI
Konishi 2013 [45] (n = 330)
Study design: Prospective cohort study
Follow-up (median): 4.7 yrs
Population description: Mixed gender Japenese
adults≥ 18 yrs undergoing PCI with achieved
lipid targets: Lp(a) ≥30 mg/dl
Risk of bias assessment overalla: High
Funding: Public
Model: Cox proportional hazards and multivariable analysis
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: All-cause death and ACS
Lp(a) assay: Isoform independence – NR/unclear; NR if fresh or
frozen samples
Lp(a) comparison type: Categorical
Two effect sizes reported and both statistically significant showing a positive
association (same direction):
≤ 30 mg/dl (reference) vs. ≥30 mg/dl: HR 1.68, 95 % CI: 1.03 to 2.7 (Cox
proportional hazards)
≤ 30 mg/dl (reference) vs. ≥30 mg/dl: HR 2.47, 95 % CI: 1.19 to 5.06
(multivariable analysis)
Results showed that high Lp(a) [ ≥30 mg/dL] could independently predict
major adverse events
Kwon 2015 [73] (n = 1494)
Study design: Prospective cohort study
Follow-up (mean): 4.4 (SD 2.6) yrs
Population description: Mixed gender Korean
adults≥ 18 yrs with diabetes and a history of
symptomatic CAD including IHD, stable/unstable
angina, and MI
Risk of bias assessment overalla: Moderate
Funding: Public
Model: Cox proportional regression analysis
Variables: Age, gender and other variables; LDL-C leven not
included (hyperlipidemia defined as LDL-C of at least
130 mg/dL was included)
CVD Outcomes: MACE
Lp(a) assay: Isoform independent; NR if fresh or frozen samples
Lp(a) comparison type: Categorical
Two effect sizes (adjusting for age, gender, hypertension, hyperlipidemia,
smoking and extent of CAD) reported and both statistically significant showing
a positive association (same direction) with risk of MACE:
Tertile 1 (median 4.7 mg/dL; reference) vs. Tertile 2 (median 13.5 mg/dL): HR
1.54, 95 % CI: 0.68 to 3.50
Tertile 1 (median 4.7 mg/dL; reference) vs. Tertile 3 (median 38.8 mg/dL): HR
2.89, 95 % CI: 1.37 to 6.08
In addition, a survival probability plot according to Lp(a) tertile suggested that
elevated Lp(a) level was associated with a worse prognosis (p = 0,008) after
adjusting for age, gender, hypertension, hyper lipidemia, smoking and extent
of CAD.
Results suggested elevated Lp(a) is associated with worse outcomes (MACE)
in type 2 diabetics patients with symptomatic CAD and has incremental
prognostic value.
LIPID [13] (n = 3949)
Study design: RCT
Follow-up: 6 yrs and 8 yrs
Population description: Mixed gender White
adults≥ 18 yrs with history of CVD (Lp(a)
13.9-44.1 mg/dl)
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: Total CHD events (non-fatal MI, CHD death,
unstable angina, coronary revascularization)
Lp(a) assay: Isoform independent; frozen samples
Lp(a) comparison type: Categorical
36 effect sizes were reported across 3 different comparisons and 12 different
CVD outcomes. 11/39 effect sizes were statistically significant analyses (all
positive association (same direction). Effect size ranges were:
From≤ 13.9 mg/dl (reference) vs. >73.7 mg/dl: HR 1.21, 95 % CI: 1.07 to 1.36)
To≤ 13.9 mg/dl (reference) vs. >73.7 mg/dl: HR 1.45, 95 % CI: 1.2 to 1.75















Table 4 Summary of studies in secondary prevention (14 studies) (Continued)
Risk of bias assessment overalla: Moderate
Funding: Industry
Overall, the authors concluded that baseline Lp(a) and increased Lp(a)
concentrations after one year were independently associated with future
cardiovascular disease and CHD events.
Park 2015 [72] (n = 161)
Study design: Prospective cohort study
(retrospective analysis of prospective
registry data)
Follow-up (median): 6 yrs (maximum: 8 yrs)
Population description: Mixed gender adults≥
18 yrs undergoing PCI
Risk of bias assessment overalla: Moderate
Funding: NR
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C included
CVD Outcomes: MACE
Lp(a) assay: Isoform independence – NR/unclear; NR if fresh
or frozen samples
Lp(a) comparison type: Categorical
Cox proportional hazards regression analysis adjusted for gender, age, diabetes
mellitus, hypertension, hyperlipidemia, smoking, multivessel disease, minimal
luminal diameter after PCI, reference vessel diameter after PCI, LDL-C, total
lesion length, Lp(a)≥ 50 mg/dL, showed that Lp(a) > 50 mg/dL (vs. Lp(a)≤
50 mg/dL) was significantly associated with the 3 yr adverse clinical outcomes
including any MI, revascularization (target lesion revascularization (TLR) and
target vessel revascularization (TVR)), TLR- MACEs, TVR-MACE, and All-MACEs.
One significant effect size: OR 2.88, 95 % CI: 1.37 to 6.07.
Authors concluded that high Lp(a) level ≥ 50 mg/dL in angina pectoris
patients undergoing elective PCI with DES was significantly associated with
binary restenosis and 3 yr adverse clinical outcomes in an Asian population.
RESEARCH [74] (n = 161)
Study design: Prospective cohort study
Follow-up (median): 6 yrs (maximum: 8 yrs)
Population description: Mixed gender adults≥
18 yrs undergoing PCI
Risk of bias assessment overalla: Moderate
Funding: NR
Model: Cox proportional hazards
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: MACE
Lp(a) assay: Isoform independent; frozen samples
Lp(a) comparison type: Categorical
Eight effect sizes reported. Five out of eight effect sizes were statistically
significant and all were positive association (same direction). These ranged
from:
Lp(a) tertile 1 (cut point 0.27 mg/dl - reference) vs. Lp(a) tertile 3 (>
1.83 mg/dl): HR 1.9, 95 % CI: 1 to 3.5
To Lp(a) tertile 1 (cut point 0.27 mg/dl - reference) vs. Lp(a) tertile 2
(cutpoint 1.83 mg/dl: HR 3.7, 95 % CI: 1.4 to 10.1
Three out of eight analyses were NS
The results showed that high levels of Lp(a) were independently
associated with a higher 1-year risk of MACE,
Rosengren 1990 [75] (n = 155)
Study design: Nested case-control study
Follow-up: 6 yrs
Population description: Males≥ 50 yrs with
MI or CHD death
Risk of bias assessment overalla: Moderate
Funding: Mixed (foundation/ public)
Model: Logistic regression
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: CHD deaths and non-fatal MI
Lp(a) assay: Isoform independence – NR/unclear; frozen samples
Lp(a) comparison type: Categorical
One effect size reported for the comparison of controls (reference) vs.
cases. This was reported as statistically significant difference for the
unconditional likelihood estimate (0.0031) suggesting a positive
association (same direction)
The results show that serum Lp(a) concentration is an independent
risk factor for subsequent MI or death from CHD
TNT Study [76] (n = 1506)
Study design: RCT
Follow-up (median): 4.9 yrs
Population description:Mixed gender adults≥
40 yrs who have experienced major
cardiovascular events and are receiving
statin treatment
Risk of bias assessment overalla: High
Funding: Pharma
Model: Cox proportional hazards regression
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: CHD death; non-fatal, non-procedure-related
myocardial infarction; resuscitated cardiac arrest; and fatal
or nonfatal stroke.
Lp(a) assay: Commercial assay; Immunoturbidimetric assay;
Isoform dependence - NR/unclear; NR if fresh or frozen samples
Lp(a) comparison type: Categorical
Three effect sizes reported. Two out of three effect sizes were statistically
significant and all were positive association (same direction).
One effect size was reported in whole population for Lp(a) with major
CV events: HR 1.17, 95 % CI: 1.04 to 1.33. Other significant effect size was
reported in subgroup atorvastatin 10 mg QD for Lp(a) with major CV
events: HR 1.34, 95 % 1.12 to 1.6.
No significant effect in Atorvastatin 80 mg subgroup 1.01 (95 % CI
0.85 to 1.20)
Results suggest that higher plasma levels of Lp(a) are independently















Table 4 Summary of studies in secondary prevention (14 studies) (Continued)
Wehinger 1999 [77] (n = 2223)
Study design: Prospective cohort study
Follow-up: 1 yr
Population description: Mixed gender adults≥
18 yrs successfully treated with intracoronary
stent due to symptomatic CAD
Risk of bias assessment overalla: Moderate
Funding: NR
Model: Log-rank test
Variables: Age, gender and other variables; LDL-C not included
CVD Outcomes: Angiographic restenosis
Lp(a) assay: Isoform independence – NR/unclear; fresh samples
Lp(a) comparison type: Categorical
Four effect sizes reported. All were NS for the comparison between
Lp(a) quintiles (2 to 3) vs. Lp(a) quintile 1.
Results suggest that elevated Lp(a) levels did not influence the one-year
clinical and angiographic outcome after stent placement. Thrombotic
events and measures of restenosis were not adversely affected by the
presence of high Lp(a) levels.
a Overall risk of bias as assessed by QUIPS tool [24]
4S Scandinavian Simvastatin Survival Study; ACS acute coronary syndrome; AIM-HIGH Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes; CABG
coronary artery bypass grafting; CAD coronary artery disease; CHD coronary heart disease; CI confidence interval; CVD cardiovascular disease; dl decilitre; GENERATION Global Evaluation of New Events and Restenosis
After Stent Implantation; HDL high-density lipoprotein; HERS Heart and Estrogen/progestin Replacement Study; HR hazard ratio; LDL-C low-density lipoprotein; l litre; LIPID Long-Term Intervention with Pravastatin in Is-
chaemic Disease; Lp(a) lipoprotein a; max maximum; MACE major coronary events; mg milligram; MI myocardial infarction; min minimum; NR not reported; NSTACS non-ST-segment elevation acute coronary syndrome;
PCI percutaneous coronary intervention; PTCA percutaneous transluminal coronary angioplasty; QUIPS Quality In Prognosis Studies; RCT; ref reference; RESEARCH Rapamycin-Eluting Stent Evaluated At Rotterdam Cardi-















hyperlipidemia (defined as LDL-C ≥ 130 mg/dL) as a
variable in the multivariable model. This study also
concluded that elevated Lp(a) is associated with worse
outcomes (MACE) in type 2 diabetics patients with
symptomatic CAD (Tertile 1 [median 4.7 mg/dL; refer-
ence] versus Tertile 2 [median 13.5 mg/dL]: HR 1.54, 95 %
CI: 0.68 to 3.50 and Tertile 1 [median 4.7 mg/dL; refer-
ence] versus Tertile 3 [median 38.8 mg/dL]: HR 2.89, 95 %
CI: 1.37 to 6.08).
Five studies (HERS; [70] Ezhov 2014; [68] LIPID; [13]
Kwon 2015; [73] and RESEARCH [74]) reported the use
of an isoform independent Lp(a) assay. All of these stud-
ies concluded that increased baseline [13, 68, 70, 72] or
follow-up [13] Lp(a) concentration was a significant and
independent risk factor for CVD events including recur-
rent CHD [70], MACE [68, 73], total CHD events [13]
and prognosis after PCI [74]. HERS [70] reported that
increased baseline Lp(a) concentrations (≥ 25.4 mg/dL)
of Lp(a) were associated with significant and independ-
ent increased in CHD (HRs between 1.01 and 1.31).
Ezhov 2014 [68] reported that stable CHD patients with
Lp(a) ≥30 mg/dL were at a significantly greater risk of
cardiovascular death and MI (HR 2.98, 95 % confidence
interval [CI]: 1.76 to 5.03) and cardiovascular death, MI,
hospitalization for recurrent or unstable angina and re-
peat revascularization (HR 3.47, 95 % CI: 2.48 to 4.85),
than patients with Lp(a) values <30 mg/dL. The LIPID
[13] study as reported that increased baseline Lp(a) con-
centrations were independently associated with an in-
creased risk of total CHD events (p < 0.001), total
cardiovascular disease events (p = 0.002), and coronary
events (p = 0.03). The authors also reported that the great-
est risk occurred at Lp(a) concentrations >73 mg/dL
(upper decile) and that an increase in Lp(a) concentration
at 1 year was associated with an increased risk of total
CHD events and total cardiovascular disease events (both
p = 0.002). The RESEARCH [74] study concluded that
there was a significant and independent association
between Lp(a) concentrations before PCI and a higher risk
of MACE at 1-year follow-up (HR 3.1, 95 % CI: 1.1 to 8.6
for the highest versus [≥ 65.2 nmol/L] the lowest tertile
[<9.8 nmol/L]). However, the authors reported that this
association weakened and lost significance with long-term
follow-up.
Overall, half of the studies included Lp(a) level as a
continuous variable and the other half of the studies
used categorical data. Where Lp(a) was assessed as a cat-
egorical value, the thresholds for the categories differed
between studies. Across all of the 14 studies, 91 effect
sizes were reported for the association between Lp(a)
and CVD events, 36 were statistically significant, show-
ing a positive association, between increased Lp(a) levels
and the risk of CVD events (HRs ranged from 0.75 to
3.7). Only one study reported a negative association
(Wehringer 1999 [77]), which was not statistically sig-
nificant. This study concluded that elevated Lp(a) mass
did not influence the one-year clinical and angiographic
outcome after stent placement [77].
The remaining 53 analyses suggested that Lp(a) pre-
dicted CV outcomes (HRs ranged from 1.21 to 3.7),
though not all of the effect sizes were statistically signifi-
cant. This included results from five studies (4S study;
[66] GENERATION; [69] HERS; [70] LIPID; [13, 74]
and RESEARCH [74]). Although some non-significant
results for subgroup and sensitivity analyses were re-
ported in these five studies, all concluded that high
Lp(a) concentrations (range ≥ 25 to 65.2 mg/dL) were
significant predictors of CVD events, including in popu-
lations of postmenopausal women with CHD [70], pa-
tients with previous CHD [66], stable CHD [13], stable
and unstable coronary syndromes after coronary stenting
[69] and short term progress after PCI [74].
Discussion
This review presents contemporary evidence examining
the extent of relationship between Lp(a) levels and CVD
outcomes. The strengths of the review include the ad-
herence to validated rigorous systematic review method-
ology. This is also one of the first systematic reviews to
examine high risk primary prevention patients and sec-
ondary prevention populations separately, while only fo-
cusing on evidence from multivariable analyses which
took into consideration potential confounders.
Our review suggests that evidence is available to support
an independent positive association between Lp(a) and the
risk of future CVD events both in the general population
and in high risk populations, such as those with diabetes,
hypertension, or on dialysis. Evidence also exists to support
the positive independent association of Lp(a) mass with
CVD events in secondary prevention populations. The
number of studies for high risk primary prevention popula-
tions and secondary prevention populations was limited.
Our findings confirm previous reviews of primary pre-
vention studies; [16, 18] including a review by the Emer-
ging Risk Factors Collaboration published in 2009. This
review of 37 prospective studies (n = 1,40,956) reported
that Lp(a) modelled as continuous and categorical vari-
ables, was an independent risk factor for coronary heart
disease death, nonfatal MI, and stroke [16]. The review
used individual patient data from the included studies
and focused on the primary prevention of coronary heart
disease, stroke and non-vascular mortality. In compari-
son, our review was based on study level data and in-
cluded a much broader range of CVD outcomes and
encompasses primary prevention in high risk population
and secondary prevention populations.
Our review found four out of 57 studies which con-
cluded that Lp(a) mass was not a predictor of subsequent
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events. This included three primary prevention studies
[33, 39, 51] in the general population and one in a high
risk population [58]. The study in a high risk population
reported that in stable haemodialysis patients measuring
outcomes at two years, Lp(a) mass was related to the de-
velopment of overall death and cardiovascular death, but
suggested that it was involved in an acute phase reaction
and successful treatment of the inflammatory condition
may improve long-term survival and so explain the lack of
an association with mortality in these patients [58]. The
primary prevention studies in the general population con-
cluded that there was no overall statistically significant as-
sociation between Lp(a) mass and the risk of all-cause
mortality, cumulative fatal–nonfatal stroke, and cumula-
tive fatal–nonfatal CAD events [51], ischemic stroke in
postmenopausal women [39] and peripheral arterial dis-
ease in men [33]. This may have been due to inadequate
measurement methods for Lp(a) in comparison with other
primary prevention studies, although methods were not
always clearly described with respect to their isoform in-
dependence [39].
With respect to the relationship between Lp(a) mass and
the secondary prevention of CVD outcomes, our review
found some evidence to support a positive association in
agreement with previous reviews in this population
[81, 82] including a recent review by O’Donoghue [20].
Unlike our review, O’Donoghue and colleagues had access
to individual patient data from three studies (PEACE –
Prevention of Events with Angiotensin Converting
Enzyme Inhibition; [83] CARE - Cholesterol and
Recurrent Event); [84] and PROVE IT–TIMI 22 -
Pravastatin or Atorvastatin Evaluation and Infection
Therapy–Thrombolysis In Myocardial Infarction 22 [85]
trials) and were able to pool these data. When combined
with in some cases unpublished data from eight previous
studies (FATS - Familial Atherosclerosis Treatment Study;
[86] 4S; [66] HERS; [70] GENERATION; [69] Saely 2006;
[87] Skinner 1997; [88] Stubbs 1998; [89] and AIM-HIGH
[67]) the authors also found a significant association be-
tween Lp(a) and the risk of future myocardial infarction,
MACE (OR 1.40, 95 % CI: 1.15 to 1.71). This suggests that
although our review did not necessarily have access to all
of these trial data, similar conclusions were evident.
Only one study [77] in our review concluded that ele-
vated Lp(a) levels were not predictive of CVD events
after stent placement. In this case, Lp(a) mass was found
not to influence the one-year clinical and angiographic
outcome after stent placement, but the study did not use
a standardised assay for Lp(a) level determination and
may have been confounded by the use of antithrombotic
drugs post stent placement [77]. Previous reviews in sec-
ondary prevention have similarly reported a positive as-
sociation between Lp(a) and CVD event for populations
including those who have experienced a stroke [81], and
patients who have experienced in-stent restenosis after
coronary stenting [82]. However, unlike our review these
reviews have not focused specifically on multivariable
studies to control for confounding factors.
The relationship between Lp(a) mass and stroke is of
particular interest clinically and our review suggests that
there is evidence to suggest a significant positive relation-
ship between Lp(a) and non-haemorrhagic stroke in high
risk [54, 65] and secondary prevention [67] populations,
in agreement with the findings of other recent reviews
[16]. However, the risk relationship in the general popula-
tion was not as clearly defined, with the suggestion that an
effect is only present in certain subgroups of the popula-
tion. For instance, Lp(a) appeared to independently
predict fatal and non-fatal stroke/TIA in middle-aged
men [26], but not for ischemic stroke in postmenopausal
women [39]. The effects of Lp(a) levels on stroke includ-
ing ischemic stroke were not as well investigated however,
and there is a need for more well designed studies to look
at the specific effects of Lp(a) with regard to the different
stroke subtypes including ischemic stroke.
The identification of Lp(a) as a potential risk factor for
CVD/CHD risk prompts the question as to whether this
would be an appropriate biomarker for risk stratification
and screening [90]. To date, RCTs have not been per-
formed in patients with elevated Lp(a) levels that were
randomized to a therapy, primarily due to lack of thera-
peutic agents developed specifically to lower Lp(a). In
addition, there is also a lack of clinical trial evidence to
show that Lp(a) reduction (independent of effects on
LDL-C) lowers CVD event risk. Only half of the studies
in our review included LDL-C as a variable in the multi-
variable model. Despite this, some studies have suggested
a genetic basis for a link between Lp(a) and CVD.
Evidence from multiple genome wide association [91, 92]
and Mendelian randomization studies [93], suggested that
LPA gene variants (encoding Lp(a) lipoprotein) were
strongly associated with both an increased level of Lp(a)
lipoprotein and an increased risk of coronary disease.
However, a more recent Mendelian randomization study
has suggested that Lp(a) promotes CVD through athero-
sclerotic stenosis whereas possible prothrombotic effects
appear less influential [94]. In addition, evidence suggests
that Lp(a)-lowering therapy such as a Lp(a) apheresis with
immunabsorption against human apo(a) results in a
significant improvement in the stenosis of the coronary
arteries without evidence of other major changes in the
lipid profile [95].
In addition, Lp(a) may enhance risk discrimination
and reclassification; a recent study on the predictive role
of Lp(a) in long-term (15 years) CVD outcomes in gen-
eral community showed that the net reclassification im-
provement afforded by Lp(a) was as high as 39.6 % in
intermediate-risk group and indicated that Lp(a) can
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modify clinical risk assessment [96, 97]. The 2015 Na-
tional Lipid Association recommendations for patient-
centered management of dyslipidemia suggest that the
presence of Lp(a) levels of 50 mg/dL or more may war-
rant moving a patient into a higher risk category [98].
Similarly, the European Atherosclerosis Society consen-
sus panel recommends screening for elevated Lp(a) in
those at intermediate or high CVD/CHD risk and a de-
sirable level <50 mg/dL as a function of global cardio-
vascular risk [18]. This would also suggest that current
and future treatments which reduce Lp(a) levels, such
as apheresis [95, 99], antisense therapy which targets
Apo(a) [100] and PCSK9 inhibitors [10, 101, 102] could
provide additional benefit in the treatment of patients at
risk of CVD beyond LDL-C lowering [18], and evidence of
such additional benefit beyond LDL-C lowering should be
investigated further in ongoing and future trials [103].
The analysis within our review was limited by the inabil-
ity to carry out statistical pooling/meta-analysis. This was
not possible due to the considerable variation in out-
comes, modelling and Lp(a) assays used. Little can also be
concluded about the concurrent effects of LDL-C and
Lp(a) as very few of the included studies considered both
LDL-C and Lp(a) as model variables. Poor reporting of
study methodology in some of the studies also hampered
the conduct of the review, particularly during the study se-
lection process and the risk of bias assessment. In
addition, in some cases relevant data for studies were not
available from individual study publications and were only
available in pooled analyses from groups of trialists, which
were not eligible for inclusion in our review.
Issues with Lp(a) measurement were also problematic
and hampered interpretation as has been noted by previ-
ous review authors [11, 104]. The methods used to meas-
ure Lp(a) mass were also poorly reported. At present
research suggests that there are no commercially available
assays that are completely and truly insensitive to the vari-
ability in Lp(a) particle mass, and so the development of
assays which are mass-insensitive are key to the future
interpretation of Lp(a) risk prediction studies [104]. How-
ever, for the purposes of this review we have used the
authors’ description to classify whether studies were iso-
form dependent or independent. In the majority of cases
the classification was either not reported or unclear. How-
ever, the authors of one study (Cho 2010 [46]) clearly
reported that the test used was isoform dependent and 17
studies that the test used was isoform independent
(CCHS; [97] Chin-Shan Community Cardiovascular Co-
hort Study; [42] CHOICE; [53] CHS; [105] D’Angelo 2006;
[106] EPIC; [107] Ezhov 2014; [68] FHS; [108] GRIPS; [28]
HERS; [70] HPFS; [32] LIPID; [13] Lipid Research Clinics
Coronary Primary Prevention trial; [35] NHS; [109] RE-
SEARCH; [74] Saely 2006; [87] and WHS [40]). No obvi-
ous differences between these two sets of studies were
evident in terms of the significance and direction of effects
for the relationship. All of the studies of high risk preven-
tion and secondary prevention population that reported
the use of an isoform independent test concluded that
Lp(a) was an independent risk factor for CVD events.
Future studies should ensure that their methodology, in-
cluding Lp(a) assay methods is clearly reported, given the
potential issues relating to the reliability of Lp(a) measure-
ment and comparability between assays.
Conclusions
There is evidence to suggest that increased Lp(a) levels
are associated with modest increases in the risk of future
CVD in both of the lower and higher risk populations
reviewed. Therapies that provide Lp(a) lowering in
addition to LDL-C lowering such as PCSK9 inhibitors and
antisense therapy which targets Apo(a), should be investi-
gated for additional benefit in these populations beyond
the expected benefits of the LDL-C lowering.
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